Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amphastar Pharmaceuticals ( (AMPH) ) just unveiled an update.
On September 15, 2025, Amphastar Pharmaceuticals entered into a contract research agreement with Nanjing Hanxin Pharmaceutical Technology to develop Recombinant Peptide Research Cell Banks for the company. This agreement, valued at approximately $2.8 million, grants Amphastar exclusive rights to the developed cell banks and associated proprietary information. The deal was approved by the independent members of Amphastar’s Audit Committee due to potential conflicts of interest, as the company’s executives hold significant equity in Hanxin.
The most recent analyst rating on (AMPH) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock, see the AMPH Stock Forecast page.
Spark’s Take on AMPH Stock
According to Spark, TipRanks’ AI Analyst, AMPH is a Neutral.
Amphastar Pharmaceuticals’ overall stock score reflects strong financial stability and reasonable valuation. However, challenges such as declining revenue growth, increased competition, and mixed technical signals weigh on the score. Strategic expansions and product pipeline advancements provide potential for future growth.
To see Spark’s full report on AMPH stock, click here.
More about Amphastar Pharmaceuticals
Amphastar Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and manufacturing of pharmaceutical products. The company is involved in creating recombinant peptide research cell banks and other related biotechnological products.
Average Trading Volume: 531,395
Technical Sentiment Signal: Sell
Current Market Cap: $1.25B
For an in-depth examination of AMPH stock, go to TipRanks’ Overview page.